Continuous Infusion of Nefopam for Patients Undergoing Pancreatoduodenectomy A Randomized Controlled Double-Blind Trial

What this Trial Is About

Researchers are evaluating whether continuous administration of nefopam, as part of a multimodal pain management strategy, can reduce opioid use and improve patient satisfaction after pancreatoduodenectomy surgery. The study compares nefopam with two other pain control methods: continuous lidocaine infusion and epidural analgesia. The main questions focus on whether nefopam lowers opioid consumption and postoperative pain levels following this surgery. Participants will be randomly assigned to one of three groups: one receiving standard multimodal analgesics plus epidural analgesia, another receiving standard multimodal analgesics plus continuous nefopam infusion starting during surgery and continuing for 48 hours after, and a third receiving standard multimodal analgesics plus continuous lidocaine infusion during the same periods. All groups receive standard postoperative care including paracetamol. During the study, participants will complete the Quality of Recovery (QoR-15) questionnaire and report pain levels at set times before and after surgery. Researchers will measure opioid use and pain levels from enrollment through 48 hours post-surgery, monitor adverse events, and assess recovery quality. The total participation period focuses on the first 48 hours after surgery for these assessments.

Continous Infusion of Nefopam for Patients Undergoing Pancreatoduodenectomy